Cue Biopharma, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $27.5M | $9.3M | $5.5M | $1.2M | $14.9M |
| Research and development | $37.7M | $36.3M | $40.8M | $38.6M | $41.3M |
| Operating expenses | $54.0M | $50.8M | $57.6M | $54.5M | $58.7M |
| Operating income | -$26.6M | -$41.5M | -$52.1M | -$53.2M | -$43.7M |
| Interest expense | $100,000 | $100,000 | $100,000 | $109,000 | — |
| Pretax income | — | — | — | -$53.0M | -$43.7M |
| Income tax expense | $500,000 | $0 | — | $0 | $495,000 |
| Net income | -$26.6M | -$40.7M | -$50.7M | -$53.0M | -$44.2M |
| Balance Sheet | |||||
| Cash and equivalents | $27.1M | $22.5M | $48.5M | $51.6M | $64.4M |
| Current assets | $37.0M | $25.1M | $51.5M | $77.2M | $68.5M |
| Total assets | $42.2M | $32.2M | $61.5M | $91.3M | $83.4M |
| Current liabilities | $13.5M | $13.7M | $17.1M | $11.5M | $12.8M |
| Total liabilities | $15.8M | $14.7M | $24.4M | $25.6M | $17.9M |
| Total debt | — | — | $8.0M | $10.0M | — |
| Stockholders' equity | $26.4M | $17.5M | $37.1M | $65.7M | $65.5M |
| Cash Flow Statement | |||||
| Cash from operations | -$21.7M | -$36.3M | -$40.0M | -$41.8M | -$38.8M |
| Depreciation and amortization | $336,000 | $385,000 | $545,000 | $831,000 | $909,114 |
| Stock-based compensation | $4.7M | $6.8M | $8.2M | $9.5M | $11.5M |
| Capital expenditure | $177,000 | $66,000 | $0 | $171,000 | $913,039 |
| Free cash flow | -$21.9M | -$36.4M | -$40.0M | -$42.0M | -$39.8M |
| Share repurchases | — | — | $0 | $200,000 | $750,128 |
Shares outstanding 4.0M · Free float 56.1%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.